Japanese trial to look at doxorubicin combination for ovarian cancer
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceutical in Japan is to investigate the combination use of its anticancer drug Doxil (liposomal doxorubicin) for ovarian cancer in a research collaboration with a leading local university.